BPC-157: what the evidence actually shows

BPC-157 is a synthetic 15-amino-acid peptide marketed for faster healing of tendons, ligaments, muscle and gut tissue, and nearly all of the evidence behind those claims comes from rats. A 2025 systematic review found 35 preclinical studies and one small human study in sports medicine, and no study that assessed its safety in people. It is not FDA approved, and it is banned in tested sport.

That is the direct answer. The more useful question for a founder is why a compound with this little human data has become the default recommendation in every performance group chat, and how to think about it the way you would think about any bet with a thin data room.

What is BPC-157, and why is everyone talking about it?

BPC stands for "body protection compound." Researchers describe it as derived from a "naturally occurring peptide in gastric juices" that helps protect the lining of the stomach. The version sold today is made in a lab. Operation Supplement Safety, the U.S. Department of Defense's dietary supplement resource, calls it "a laboratory-made, synthetic peptide made up of 15 amino acids."

The story that sells it goes like this. In animal experiments, BPC-157 appears to speed up repair of cut tendons, crushed muscle and damaged ligaments. It seems to act on blood vessel growth and cell migration, the machinery tissue uses to heal. So if you have a cranky Achilles, a shoulder that has not been right since you tried to keep up at the company offsite, or a gut that falls apart during every fundraise, it sounds like exactly what you need.

It also has a reputation as the "safe" peptide, the one people start with. That reputation is doing a lot of work, because it is built on an absence of reported harm rather than on studies designed to find harm.

What does the research on BPC-157 actually include?

The best single map of the evidence for musculoskeletal use is a 2025 systematic review in HSS Journal, written by orthopaedic surgeons, titled "Emerging Use of BPC-157 in Orthopaedic Sports Medicine." The authors searched the literature from 1993 to 2024 and identified 544 articles. After removing duplicates and screening, they included 36 studies. Thirty-five were preclinical, meaning animal or cell work. One was clinical.

The animal data: interesting, consistent and mostly in rats

The preclinical work is where the enthusiasm comes from, and to be fair, it is not nothing. Across tendon, muscle, ligament and bone injury models, the animal studies in the review generally report faster or better healing. The review describes plausible mechanisms: BPC-157 "stimulates vascular endothelial growth factor (VEGF) protein and gene expression, a pathway commonly implicated in angiogenesis," the formation of new blood vessels, and it increases activity of ERK1 and ERK2, signaling molecules "involved in cell growth, migration, and angiogenesis."

The animal models were predominantly male Wistar rats, with one rabbit study. Most injuries were created surgically: a tendon cut through, a muscle crushed.

Here is why that matters. A surgically transected rat tendon in a young, healthy lab animal is a very different problem from a 46-year-old executive's degenerative Achilles that has been aggravated for two years by travel, bad sleep and weekend running. Young lab animals heal well. Human outcomes like pain are also self-reported, often by people who paid for the treatment and want it to work, which is exactly why human trials need a control group. Plenty of compounds that work beautifully in rodent models never show the same effect in humans. That is not a knock on BPC-157 specifically. It is the base rate for translational research.

The human data: one retrospective study of 12 people

The single clinical study in the review was a retrospective look at patients who had received injections of BPC-157 into the knee for unspecified chronic knee pain. Seven of 12 patients reported relief lasting more than six months.

Consider what that design can and cannot tell you. There was no control group, so there is no way to separate the compound from placebo, from the natural course of knee pain, or from whatever else those patients were doing. It was retrospective, meaning researchers looked back at records rather than setting up a trial in advance. The pain had no specified cause. And 12 people is far too few to detect uncommon side effects.

If a startup came to you with a claim built on a pitch deck of 35 rat experiments and one uncontrolled customer case study of 12 users, you would call it a hypothesis worth testing. That is exactly what BPC-157 is.

The review's own conclusion is measured: "Due to limited high-quality clinical evidence, clinicians and athletes should exercise caution when considering the use of BPC-157."

Is BPC-157 safe? What we know and what we don't

The most important line in the review is this one: "No study assessed the safety or adverse events of BPC-157 in humans."

That is different from saying it is dangerous. It means nobody has run the kind of study that would tell you. The confident claims that BPC-157 has "no side effects" rest on the absence of a signal in research that was never designed to look for one.

FDA's position is similarly plain. In its published safety review of substances nominated for compounding, the agency says compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization." In plain terms: it could provoke an immune reaction, it may contain impurities, and it is hard to confirm what is actually in the vial. FDA adds that it "has identified no, or only limited, safety-related information for the proposed routes of administration," and so "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."

The angiogenesis question

The mechanism that makes BPC-157 exciting is also the one that deserves the most caution. Growing new blood vessels helps an injured tendon heal. Blood vessel growth is also something tumors rely on. The review documents that BPC-157 stimulates VEGF signaling. Whether that has any meaningful effect on existing or undetected cancers in humans is simply unstudied. There is no human evidence that it does, and there is no human evidence that it does not.

For a healthy 35-year-old that may feel abstract. For a 55-year-old with a family history of cancer, it is a question worth raising with a physician before anything else.

The product-quality problem

Even if BPC-157 turns out to be both safe and effective, the stuff most people are using is not a pharmaceutical product. Operation Supplement Safety notes that BPC-157 turns up in health and wellness products, sometimes sold as "research chemicals" with labels such as "Not for human consumption" or "Research use only." Those labels exist for a reason: nobody is certifying the identity, purity, sterility or dose of what is inside. With an injectable, contamination and sterility are not minor details.

What is BPC-157's legal and FDA status?

FDA: BPC-157 is not an FDA-approved drug. OPSS states that "It is an unapproved drug and cannot be legally prescribed or sold over the counter." According to the HSS Journal review, FDA named BPC-157 a Category 2 bulk drug substance in 2023, the list of compounding ingredients FDA says raise significant safety concerns. Compounding rules for peptides have been in flux in 2026, and FDA's April 2026 update of its safety review lists BPC-157 among nominated substances whose nominations were withdrawn. Whatever happens next with compounding, keep one distinction clear: a change in who may legally prepare a substance is not an approval. It does not establish that the substance works, a safe dose, or who should and should not take it.

Sport: BPC-157 is listed in class S0, Non-Approved Substances, on the World Anti-Doping Agency Prohibited List. The review notes that WADA, the UFC and the NFL all introduced bans in 2022. If you compete in anything tested, including masters events and some amateur endurance races, that settles the question.

What the evidence says, and what it doesn't

Reasonably supported: In animal models, mostly rats with surgically created injuries, BPC-157 is associated with faster tissue healing, and there are plausible mechanisms involving blood vessel growth and cell migration.

Not established: That it speeds healing in humans. The only clinical study in the sports medicine literature is a retrospective series of 12 people without a control group. There are no large, randomized, placebo-controlled trials.

Unknown: Its safety in humans, including immune reactions, impurities, long-term effects and any interaction with cancer risk given its effect on angiogenesis. No study in the review assessed human safety at all.

Not what it sounds like: "No reported side effects" is not the same as "safe," and a compounding rule change is not an FDA approval.

If you are considering BPC-157 or any other peptide, hormone or unapproved compound, talk with a physician first, ideally one who will be candid about how thin the human evidence is.

What a founder can actually do this week

The real problem behind most BPC-157 questions is an injury that is not healing and a schedule that does not allow for it to heal. Those have better-evidenced answers.

Get a diagnosis. If a tendon, joint or muscle has bothered you for more than a few weeks, see a sports medicine physician or physical therapist. Knowing whether you have a tendinopathy, a partial tear or a referred problem changes everything about what works. A loading program built for your specific injury has far more human evidence behind it than any peptide.

Treat sleep as part of the rehab plan. Tissue repair happens on the body's schedule, and the body does much of that work at night. If you are running the company on six hours and a red-eye, fix that before you look for a compound to compensate. The wind-down routine in meditation for sleep for executives is a practical place to start.

Look at total load, not just training load. A body under chronic stress recovers more slowly, and founders often underestimate how much the job itself is taxing them. Our piece on what chronic stress does to a founder's body lays out the physiology.

Run the decision like an investment memo. Before trying anything unproven, write down three things: what evidence would convince you it works, what side effect would make you stop, and who is independently checking what is in the product. If you cannot answer all three, you are the experiment, without an ethics board, a control group or a safety monitor.

Check your sport's rules. If there is any chance you will be tested, check with the relevant anti-doping agency before taking anything.

The part of recovery you can train

Underneath the peptide conversation is a real and reasonable desire: founders want to recover faster so they can keep performing. One recovery system you already own is your nervous system. A body that can shift out of fight-or-flight after a hard meeting, fall asleep without a racing mind and hold a regular rhythm through a chaotic quarter is a body that repairs better. That capacity responds to practice.

That is what we work on at Cinder: private 1:1 meditation coaching for founders and executives, focused on stress regulation and sleep as trainable skills. It will not repair a torn tendon. It can help you stop running at the pace that keeps producing them. If you are curious what that looks like, read why founders are hiring meditation coaches.

Where BPC-157 goes from here

BPC-157 may eventually earn a place in medicine. The animal data is interesting enough that properly designed human trials would be worth running. Until they exist, the honest summary is short: promising rat studies, one tiny human study, no human safety data, no FDA approval and a ban in sport. Build your recovery on the things with evidence behind them, and let the research catch up.

Apply for private coaching

Sources

• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal (via PMC), 2025
• Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding, U.S. Food and Drug Administration, 2026
• BPC-157: Prohibited peptide and unapproved drug found in health and wellness products, Operation Supplement Safety (U.S. Department of Defense), 2025